Marker Therapeutics Showcases MAR-T Cell Therapy Advances and MT-601 Clinical Progress in New Corporate Presentation
I'm PortAI, I can summarize articles.
Marker Therapeutics Inc. has released a corporate presentation detailing advancements in its MAR-T cell therapy platform and the clinical progress of its lead product, MT-601. The APOLLO Phase 1 trial for MT-601 shows promising results in lymphoma patients. The company highlights improvements in manufacturing and cell potency, and has secured over $30 million in non-dilutive funding. The presentation underscores Marker Therapeutics' strong intellectual property position.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments